Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Targeted next generation sequencing as a tool for precision medicine.

Gulilat M, Lamb T, Teft WA, Wang J, Dron JS, Robinson JF, Tirona RG, Hegele RA, Kim RB, Schwarz UI.

BMC Med Genomics. 2019 Jun 3;12(1):81. doi: 10.1186/s12920-019-0527-2.

2.

Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1.

Medwid S, Li MMJ, Knauer MJ, Lin K, Mansell SE, Schmerk CL, Zhu C, Griffin KE, Yousif MD, Dresser GK, Schwarz UI, Kim RB, Tirona RG.

Drug Metab Dispos. 2019 Aug;47(8):832-842. doi: 10.1124/dmd.119.087619. Epub 2019 May 23.

PMID:
31123035
3.

Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation.

Sukumar S, Gulilat M, Linton B, Gryn SE, Dresser GK, Alfonsi JE, Schwarz UI, Kim RB, Schwartz JB.

J Am Geriatr Soc. 2019 Sep;67(9):1902-1906. doi: 10.1111/jgs.15982. Epub 2019 May 21.

PMID:
31112620
4.

Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.

Ohara M, Suzuki Y, Shinohara S, Gong IY, Schmerk CL, Tirona RG, Schwarz UI, Wen MS, Lee MTM, Mihara K, Nutescu EA, Perera MA, Cavallari LH, Kim RB, Takahashi H.

Clin Pharmacokinet. 2019 Aug;58(8):1077-1089. doi: 10.1007/s40262-019-00745-5.

PMID:
30815847
5.

SLC6A3 Polymorphism Predisposes to Dopamine Overdose in Parkinson's Disease.

Robertson BD, Al Jaja AS, MacDonald AA, Hiebert NM, Tamjeedi R, Seergobin KN, Schwarz UI, Kim RB, MacDonald PA.

Front Neurol. 2018 Aug 21;9:693. doi: 10.3389/fneur.2018.00693. eCollection 2018.

6.

The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics.

Schwarz UI, Gulilat M, Kim RB.

Cold Spring Harb Perspect Med. 2019 Feb 1;9(2). pii: a033027. doi: 10.1101/cshperspect.a033027. Review.

PMID:
29844222
7.

Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease.

Tirona RG, Kassam Z, Strapp R, Ramu M, Zhu C, Liu M, Schwarz UI, Kim RB, Al-Judaibi B, Beaton MD.

Drug Metab Dispos. 2018 May;46(5):485-492. doi: 10.1124/dmd.117.079624. Epub 2018 Feb 22.

PMID:
29472495
8.

Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.

Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes AC, Alfonsi JE, Dresser GK, Henderson SL, Rose RV, Lizotte DJ, Teft WA, Schwarz UI, Tirona RG, Kim RB.

Can J Cardiol. 2017 Aug;33(8):1036-1043. doi: 10.1016/j.cjca.2017.04.008. Epub 2017 Apr 24.

PMID:
28754389
9.

Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas.

Kim M, Deacon P, Tirona RG, Kim RB, Pin CL, Meyer Zu Schwabedissen HE, Wang R, Schwarz UI.

Histochem Cell Biol. 2017 Oct;148(4):345-357. doi: 10.1007/s00418-017-1580-6. Epub 2017 May 10.

PMID:
28493059
10.

Genetic Determinants of Clozapine-Induced Metabolic Side Effects.

Vasudev K, Choi YH, Norman R, Kim RB, Schwarz UI.

Can J Psychiatry. 2017 Feb;62(2):138-149. doi: 10.1177/0706743716670128. Epub 2016 Sep 29.

11.

Genetic Predictors of Azathioprine Toxicity and Clinical Response in Patients with Inflammatory Bowel Disease.

Al-Judaibi B, Schwarz UI, Huda N, Dresser GK, Gregor JC, Ponich T, Chande N, Mosli M, Kim RB.

J Popul Ther Clin Pharmacol. 2016;23(1):e26-36. Epub 2016 Feb 22.

PMID:
26950049
12.

Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters.

Mooij MG, Schwarz UI, de Koning BA, Leeder JS, Gaedigk R, Samsom JN, Spaans E, van Goudoever JB, Tibboel D, Kim RB, de Wildt SN.

Drug Metab Dispos. 2014 Aug;42(8):1268-74. doi: 10.1124/dmd.114.056929. Epub 2014 May 14.

13.

Genotype-guided dosing of vitamin K antagonists.

Schwarz UI, Kim RB, Tirona RG.

N Engl J Med. 2014 May 1;370(18):1761-2. doi: 10.1056/NEJMc1402521. No abstract available.

PMID:
24785215
14.

Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy.

Ziada A, Schwarz UI, DeGorter MK, Tirona RG, Ban MR, Kim RB, Hegele RA.

Can J Cardiol. 2013 Nov;29(11):1395-9. doi: 10.1016/j.cjca.2013.08.003.

PMID:
24182755
15.

OATP1B3 is expressed in pancreatic β-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide.

Meyer Zu Schwabedissen HE, Boettcher K, Steiner T, Schwarz UI, Keiser M, Kroemer HK, Siegmund W.

Diabetes. 2014 Feb;63(2):775-84. doi: 10.2337/db13-1005. Epub 2013 Oct 22.

16.

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ, Wilke RA, Hegele RA, Kim RB.

Circ Cardiovasc Genet. 2013 Aug;6(4):400-8. doi: 10.1161/CIRCGENETICS.113.000099. Epub 2013 Jul 22.

17.

Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.

Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB.

Eur Heart J. 2012 Nov;33(22):2856-2464a. doi: 10.1093/eurheartj/ehs042. Epub 2012 Feb 27.

PMID:
22374717
18.

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.

Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Wells PS, Kim RB, Tirona RG.

PLoS One. 2011;6(11):e27808. doi: 10.1371/journal.pone.0027808. Epub 2011 Nov 16.

19.

Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study.

Clarke JA, Cutler M, Gong I, Schwarz UI, Freeman D, Dasgupta M.

Am J Geriatr Pharmacother. 2011 Aug;9(4):224-33. doi: 10.1016/j.amjopharm.2011.07.003. Epub 2011 Jul 30.

PMID:
21803659
20.

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.

Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB.

Blood. 2011 Sep 15;118(11):3163-71. doi: 10.1182/blood-2011-03-345173. Epub 2011 Jul 1.

21.

Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis.

Meyer zu Schwabedissen HE, Ware JA, Finkelstein D, Chaudhry AS, Mansell S, Leon-Ponte M, Strom SC, Zaher H, Schwarz UI, Freeman DJ, Schuetz EG, Tirona RG, Kim RB.

Hepatology. 2011 Aug;54(2):644-54. doi: 10.1002/hep.24391. Epub 2011 Jun 26.

22.

Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.

Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH, Kim RB.

Pharmacogenet Genomics. 2011 Mar;21(3):103-14. doi: 10.1097/FPC.0b013e328342f5b1.

23.

Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.

Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G.

Pediatrics. 2010 Oct;126(4):e986-9. doi: 10.1542/peds.2009-1907. Epub 2010 Sep 13.

PMID:
20837591
24.

Human skeletal muscle drug transporters determine local exposure and toxicity of statins.

Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG.

Circ Res. 2010 Feb 5;106(2):297-306. doi: 10.1161/CIRCRESAHA.109.203596. Epub 2009 Nov 25.

PMID:
19940267
25.

Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.

Sakaguchi S, Garcia-Bournissen F, Kim R, Schwarz UI, Nathan PC, Ito S.

Arch Dis Child. 2009 Dec;94(12):981-2. doi: 10.1136/adc.2009.163089. Epub 2009 Jul 15.

PMID:
19608554
26.

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D.

Blood. 2009 Apr 23;113(17):3925-30. doi: 10.1182/blood-2008-09-176859. Epub 2008 Dec 12.

27.

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ.

Blood. 2008 Aug 15;112(4):1022-7. doi: 10.1182/blood-2008-01-134247. Epub 2008 Jun 5.

28.

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.

Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB.

Pharmacogenet Genomics. 2008 May;18(5):439-48. doi: 10.1097/FPC.0b013e3282f974dc.

29.

Genetic determinants of response to warfarin during initial anticoagulation.

Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM.

N Engl J Med. 2008 Mar 6;358(10):999-1008. doi: 10.1056/NEJMoa0708078.

30.

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.

Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Stein CM, Kim RB.

Pharmacogenet Genomics. 2007 Aug;17(8):647-56.

31.

Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.

Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W.

Clin Pharmacol Ther. 2007 May;81(5):669-78. Epub 2007 Mar 28.

PMID:
17392718
32.

Intestinal drug transporter expression and the impact of grapefruit juice in humans.

Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB.

Clin Pharmacol Ther. 2007 Mar;81(3):362-70. Epub 2007 Jan 10.

PMID:
17215845
33.

Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition.

Schwarz UI, Johnston PE, Bailey DG, Kim RB, Mayo G, Milstone A.

Br J Clin Pharmacol. 2006 Oct;62(4):485-91.

34.

Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.

Schwarz UI, Stein CM.

Clin Pharmacol Ther. 2006 Jul;80(1):7-12. Review. No abstract available.

PMID:
16815312
35.

Grapefruit juice ingestion significantly reduces talinolol bioavailability.

Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W.

Clin Pharmacol Ther. 2005 Apr;77(4):291-301.

PMID:
15903127
36.

[Epidemiology of attempted suicide using drugs. An inquiry from the Dresden University Clinic].

Schwarz UI, Rüder S, Krappweis J, Israel M, Kirch W.

Dtsch Med Wochenschr. 2004 Jul 30;129(31-32):1669-73. German.

PMID:
15273917
37.

Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.

Schwarz UI.

Eur J Clin Invest. 2003 Nov;33 Suppl 2:23-30. Review.

PMID:
14641553
38.

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.

Dresser GK, Schwarz UI, Wilkinson GR, Kim RB.

Clin Pharmacol Ther. 2003 Jan;73(1):41-50.

PMID:
12545142
39.

Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.

Schwarz UI, Büschel B, Kirch W.

Br J Clin Pharmacol. 2003 Jan;55(1):112-3. No abstract available.

40.

MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.

Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schäkel U, Ehninger G, Schaich M.

Cancer Res. 2002 Sep 1;62(17):4955-62.

41.

Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB.

Clin Pharmacol Ther. 2002 Jan;71(1):11-20.

PMID:
11823753
42.

Identification of functionally variant MDR1 alleles among European Americans and African Americans.

Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR.

Clin Pharmacol Ther. 2001 Aug;70(2):189-99.

PMID:
11503014
43.

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.

Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI.

Mol Pharmacol. 2001 Aug;60(2):382-7.

PMID:
11455026
44.

Outpatient costs of osteoporosis in a national health insurance population.

Krappweis J, Rentsch A, Schwarz UI, Krobot KJ, Kirch W.

Clin Ther. 1999 Nov;21(11):2001-14.

PMID:
10890269
45.

P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.

Schwarz UI, Gramatté T, Krappweis J, Oertel R, Kirch W.

Int J Clin Pharmacol Ther. 2000 Apr;38(4):161-7.

PMID:
10783825
46.

Regional drug information service.

Schwarz UI, Stoelben S, Ebert U, Siepmann M, Krappweis J, Kirch W.

Int J Clin Pharmacol Ther. 1999 Jun;37(6):263-8.

PMID:
10395116
47.

Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.

Schwarz UI, Gramatté T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W.

Clin Pharmacol Ther. 1999 Mar;65(3):283-90.

PMID:
10096260
48.

Drug information services: initial experiences in Dresden.

Schwarz UI, Krappweis J, Stoelben S, Kirch W.

Eur J Clin Pharmacol. 1998 Oct;54(8):667-8. No abstract available.

PMID:
9860157

Supplemental Content

Loading ...
Support Center